Clinical trial details

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC

Identifier

MK-7684A-006

Sponsor

Merck, Sharp & Dohme de España, S.A.

Principal Investigator

PATRICIA IRANZO GOMEZ

Service

Oncology

Study details

Tumor type: LUNG-NSCLC
Stage: Early/Locally advanced
Main Investigational Agent : Immunotherapy
Phase: III
Randomization: Randomized

Molecular details

Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable

Drug details

Arm A: Durvalumab + Chemotherapy + Radiotherapy
Arm B: Pembrolizumab/Vibostolimab coformulation + Chemotherapy + Radiotherapy

Links

Clinical Trials GOV (NCT identifier): NCT05298423
EU Clinical Trials Register (eudraCT Identifier): 2021-005135-23